CereVasc raised $85 million in Series C funding to advance its minimally invasive eShunt system, which aims to treat hydrocephalus without traditional brain shunt surgery. The company is preparing for a pivotal trial completion and FDA submission in 2027.
The post CereVasc Rakes In $85M to Challenge Traditional Brain Shunt Surgery appeared first on MedCity News.
